Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.87 -0.38 (-2.34%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
From Takeda Pharmaceutical Company Limited
Via Business Wire
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to... 
Via FinancialNewsMedia
News headline image
Takeda Celebrates World Quality Week
SOURCE: Takeda 
Via 3BL Media
News headline image
Earnings Scheduled For October 28, 2021 ↗
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
News headline image
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan ↗
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd... 
Via Benzinga
News headline image
3 Stocks That Can Make You Rich in Just a Few Years ↗
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
News headline image
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients ↗
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at... 
Via Benzinga
News headline image
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
News headline image
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Happy December ↗
Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices. 
Via Talk Markets
News headline image
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More ↗
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week ↗
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
News headline image
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection ↗
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after... 
Via Benzinga
News headline image
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
News headline image
Monday Market Coverage ↗
Gold is up today on inflation fears. 
Via Talk Markets
News headline image
Takeda, Shattuck Labs Terminate Immuno-Oncology Pact ↗
Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154... 
Via Benzinga
News headline image
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
News headline image
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
No Negative Reaction ↗
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
News headline image
Takeda's 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback ↗
Takeda Pharmaceutical Company Limited (NYSE: TAK) reported 1H FY21 sales of ¥1,794.4 billion, +12.8%. Underlying core revenue increased +6.8% Y/Y, driven by 14... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.